logo
Plus   Neg
Share
Email

Moderna Says First Participant Dosed In Phase 1/2 Study Of COVID-19 Vaccine In Japan

Moderna Inc. (MRNA) said Thursday that the first participant has been dosed in the Phase 1/2 study of the company's vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co.

TAK-919 is Takeda's development code for Moderna's COVID-19 vaccine candidate.

According to the company, the placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.

Takeda plans to enroll 200 participants aged 20 years and above in Japan. Each participant will be assigned to receive a placebo or a 100 µg dose at both vaccinations. Participants will be followed through 12 months after the second vaccination, Moderna said. .

Previously, the companies said that Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021.

Moderna received authorization for its COVID-19 vaccine from regulatory authorities in the United States, Canada, Israel, the European Union, the United Kingdom and Switzerland. Additional authorizations are currently under review in other countries and by the World Health Organization.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT